This was the stock's fourth consecutive day of losses.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Abbott Laboratories (ABT) stock saw a decline, ending the day at $116.29 which represents a decrease of $-0.52 or -0.45% from the prior close of $116.81. The stock opened at $117.1 and touched a low ...

On Friday, Abbott Laboratories (ABT) stock saw a decline, ending the day at $118.93 which represents a decrease of $-0.02 or -0.02% from the prior close of $118.95. The stock opened at $118.71 and ...

Piper Sandler analyst Adam Maeder maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need ...

Abbott Laboratories (NYSE:ABT – Get Free Report) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 12,050,000 shares, a ...

Valued at a market cap of $202.6 billion, North Chicago, Illinois-based Abbott Laboratories (ABT) is a global healthcare ...

In this article, we will take a look into Abbott Laboratories's (NYSE:ABT) DCF analysis, a reliable and data-driven approach ...

Missouri judge denies Abbott Laboratories (ABT) new trial request after $500 million infant formula case verdict.

Shares of Abbott Laboratories ABT slipped 0.14% to $117.96 Tuesday, on what proved to be an all-around great trading session ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...